full name: new drug medical division of revised pharmaceutical group marketing co., ltd.
xiulaigui, chairman of the board of directors, founded Xiulaigui in May 1995, is a large-scale modern private pharmaceutical enterprise integrating scientific research, production and marketing of Chinese patent medicine, chemical pharmacy and biopharmaceuticals, drug chain management and standard cultivation of Chinese herbal medicines. At present, the Group has 66 wholly-owned and holding subsidiaries with more than 8, employees, with a total construction area of 59, square meters and total assets of 7.5 billion yuan.
Revision Pharmaceutical has a development pattern of two head offices, three national-level well-known trademarks of "Revision, Tongyao and Starshu" and fourteen sales platforms. Since 2, it has been ranked first in the comprehensive ranking of pharmaceutical enterprises in Jilin Province for 1 consecutive years, and ranked first in the profit ranking of Chinese medicine enterprises in China since 24, and its sales and profits rank among the top ten in China pharmaceutical industry. In 21, the output value was 16.9 billion yuan and the sales income was 17.1 billion yuan. From 2 to 21, the accumulated sales revenue was 55.22 billion yuan.
Revision Pharmaceutical Group has a national enterprise technology center, a national engineering center, a postdoctoral workstation, and branches in Shenyang and Shanghai. There are nearly 8 products with independent intellectual property rights and more than 1, patents. The company produces 21 dosage forms, more than 8 kinds of medicines, nearly 1, kinds of health care products and cosmetics, such as "Starshu", "Xiaomi Suppository", "Weidanning" and "Yiqi Yangxue Oral Liquid". The enterprise has won nearly 1 honors such as "May 1st Labor Award" in China.
Xiuzheng Pharmaceutical is committed to charity and social welfare undertakings, and actively participates in flood relief, SARS and snowstorm relief. It has spent more than 5 million yuan on various charitable donations and glorious undertakings, providing more than 5, jobs for the society, including 12, laid-off workers.
to build a century-old revision and create a national brand, the revision pharmaceutical industry should strive to build the largest OTC marketing network in China within 1 years, realize sales revenue of 1 billion yuan in 215 and become one of the top 1 pharmaceutical enterprises in the world in 23.
The New Drug Medical Division of Xiuzheng Pharmaceutical Group Marketing Co., Ltd. has set up offices in 3 Yu Sheng, developed more than 1, hospitals above Grade II, and has a high-quality professional medical marketing team. To revise one of the core marketing units of pharmaceutical industry.
mainly engaged in proprietary Chinese medicines, chemical preparations, antibiotics, etc. At present, there are national first-class new drugs, second-class new drugs, such as Geping, Gatifloxacin, Zhuoyi and Shuangjiangping, and exclusive varieties (including patents), such as Weidashu, Xiongdan Kaiming Tablets, Compound Wannianqing Capsules, Yangxin Anmian Capsules, etc.